Other equities analysts also recently issued reports about the stock. Bloom Burton reissued an “accumulate” rating on shares of CannTrust in a research note on Friday, March 29th. Zacks Investment Research raised shares of CannTrust from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a research note on Tuesday, April 2nd.
Shares of NYSE:CTST opened at C$5.69 on Friday. The stock has a market cap of $621.16 million, a PE ratio of -51.73 and a beta of 4.05. The company has a quick ratio of 3.38, a current ratio of 5.64 and a debt-to-equity ratio of 0.01. CannTrust has a 12 month low of C$4.35 and a 12 month high of C$11.97.
A number of hedge funds have recently added to or reduced their stakes in CTST. PNC Financial Services Group Inc. bought a new position in CannTrust in the first quarter worth about $26,000. Shell Asset Management Co. bought a new position in CannTrust in the first quarter worth about $41,000. Paragon Capital Management LLC bought a new position in CannTrust in the first quarter worth about $54,000. Winslow Evans & Crocker Inc. bought a new position in CannTrust in the first quarter worth about $56,000. Finally, Citigroup Inc. bought a new position in CannTrust in the first quarter worth about $94,000. 5.17% of the stock is owned by institutional investors.
CannTrust Holdings Inc produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc was incorporated in 2015 and is headquartered in Vaughan, Canada.
Featured Story: Stop Order Uses For Individual Investors
Receive News & Ratings for CannTrust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CannTrust and related companies with MarketBeat.com's FREE daily email newsletter.